Efficacy and safety of anticoagulant treatment using New oral anticoagulant (edoxaban) in atrial fibrillation after cardiac surgery.

Efficacy and safety of anticoagulant treatment using New oral anticoagulant (edoxaban) in atrial fibrillation after cardiac surgery. - Efficacy and safety of anticoagulant treatment using new alternative antithrombotic agents in atrial fibrillation after cardiac surgery.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021138

Enrollment

150

Registered

2016-02-23

Start date

2016-02-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arterial fibrillation after cardiac surgery (nonvalvular disease)

Interventions

New oral anticoagulant (edoxaban) for patients with atrial fibrilation after cardiac surgery 30~60mg/day for 2 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: nonvalvular atrial fibrillation patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: past of arrhythmia cardiogenic shock NYHA class IV congestive heart failure despite treatment sinus bradycardia at rest (<50/min) second -or third-degree AV block clinical hypothyroidism or hyperthyroidism Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
cerebrovascular and hemorrhagic event within 60 days	—

Secondary

Measure	Time frame
Hb,PT, APTT UCG(pericardial effusion)	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3982-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026